JPMorgan Chase & Co. Reiterates Neutral Rating for Intellia Therapeutics (NASDAQ:NTLA)

Intellia Therapeutics (NASDAQ:NTLA)‘s stock had its “neutral” rating reaffirmed by research analysts at JPMorgan Chase & Co. in a report issued on Friday, Marketbeat reports. They presently have a $13.00 target price on the stock, down from their prior target price of $45.00. JPMorgan Chase & Co.‘s target price would indicate a potential upside of 28.84% from the company’s previous close.

Other equities research analysts also recently issued reports about the company. Barclays dropped their target price on Intellia Therapeutics from $76.00 to $55.00 and set an “overweight” rating on the stock in a report on Friday, November 8th. Wedbush reiterated a “neutral” rating and set a $10.00 target price (down from $14.00) on shares of Intellia Therapeutics in a report on Friday, January 10th. William Blair reiterated a “neutral” rating and set a $14.00 target price on shares of Intellia Therapeutics in a report on Monday, November 18th. The Goldman Sachs Group dropped their target price on Intellia Therapeutics from $19.00 to $12.00 and set a “neutral” rating on the stock in a report on Tuesday, January 14th. Finally, Chardan Capital raised their target price on Intellia Therapeutics from $88.00 to $91.00 and gave the company a “buy” rating in a report on Monday, November 18th. Two investment analysts have rated the stock with a sell rating, six have given a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $42.12.

Intellia Therapeutics Price Performance

Intellia Therapeutics stock opened at $10.09 on Friday. The stock’s 50-day moving average is $10.85 and its 200-day moving average is $15.64. The company has a market cap of $1.03 billion, a price-to-earnings ratio of -1.85 and a beta of 1.80. Intellia Therapeutics has a 12 month low of $8.96 and a 12 month high of $34.87.

Insider Transactions at Intellia Therapeutics

In related news, CEO John M. Leonard sold 26,807 shares of the business’s stock in a transaction that occurred on Friday, January 3rd. The stock was sold at an average price of $12.18, for a total transaction of $326,509.26. Following the completion of the transaction, the chief executive officer now owns 941,115 shares in the company, valued at $11,462,780.70. The trade was a 2.77 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In the last quarter, insiders sold 29,000 shares of company stock worth $352,551. 3.20% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. GF Fund Management CO. LTD. acquired a new position in Intellia Therapeutics during the 4th quarter valued at approximately $25,000. Sterling Capital Management LLC boosted its position in Intellia Therapeutics by 866.2% during the 4th quarter. Sterling Capital Management LLC now owns 3,198 shares of the company’s stock valued at $37,000 after purchasing an additional 2,867 shares during the period. Whipplewood Advisors LLC acquired a new position in Intellia Therapeutics during the 4th quarter valued at approximately $40,000. Resona Asset Management Co. Ltd. acquired a new position in Intellia Therapeutics during the 4th quarter valued at approximately $43,000. Finally, Mirae Asset Global Investments Co. Ltd. boosted its position in Intellia Therapeutics by 27.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,674 shares of the company’s stock valued at $77,000 after purchasing an additional 794 shares during the period. Institutional investors and hedge funds own 88.77% of the company’s stock.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.